N/A N=288 Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System
Type 1 Diabetes Mellitus
Primary: Change in HbA1c — 7.9; 7.4; 7.4; 6.9 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=25 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes
Narcolepsy With Cataplexy
Primary: The Insulin-like Growth Factor 1 (IGF-1) Measured in Fasting Conditions at Baseline (Visit 2) — 207.4 ng/mL
Phase 1 N=12 To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.
Asthma
Primary: AUC0-t — 435; 1164 h*pg/mL
N/A N=91 Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants
Phase 2 N=60 Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus Placebo — 18; 18; 14 Participants
Phase 2 N=15 Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease
Anti-Glomerular Basement Membrane Antibody Disease
Primary: Number of Patients With Independent Renal Function at 6 Months — 5; 5; 10 Participants
N/A N=9,284 A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Incidence Rate for the First Pneumonia Event — 109.82; 167.10 patients/1000 person-years — p=<0.0001
Phase 2 N=160 An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
Depressive Disorder · Anxiety
Primary: Double-blind Treatment Period: Change From Baseline in Hamilton Depression Rating Scale (HDRS17) Total Score at Week 6 (eITT Population) — -6.1; -6.5 Units on a scale…
N/A N=153 Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)
Liver Diseases
Primary: Pathological Yield Fragmentation — 14; 11; 13; 10 mm
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
Phase 3 N=555 Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Early and Sustained (Antidepressant) Response (ESR) Rate — 17; 17; 17 Participants — p=1.000
Phase 3 N=20 Tolcapone in Obsessive Compulsive Disorder
Obsessive-Compulsive Disorder
Primary: Yale Brown Obsessive Compulsive Scale (Y-BOCS) — -4.24; -1.10 mean change in YBOCS score
Phase 2 N=25 Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
Long QT Syndrome
Primary: Change in QTc Duration at 2 Months — 503; 497 miliseconds — p=0.7958
Phase 3 N=615 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Primary: All-Cause Death: Time to Event — 8.3; 0.1; 8.3; 0.7 percentage of participants — p=<0.001
N/A N=57 Ventilation Strategies, Anesthetic Techniques and Cerebral Oxygenation in the Beach Chair Position
Stroke
Primary: Change in Regional Cerebral Oxygenation (rSO2) Before and 5 Minutes After Each Change in Ventilation Strategy — -4.27; -0.70; -15.48; -10.90 Percent oxygen saturation